AstraZeneca Raised Its 2024 Guidance: Now Expects Total Revenue And Core EPS Both Expected To Increase By A Mid-Teens Percentage (Previously Anticipated To Rise By A Low Double-Digit To Low-Teens Percentage)

Guidance
Due to strong underlying growth in Product Sales and Alliance Revenue, the Company raises its Total Revenue and Core EPS guidance for FY 2024 at CER, based on the average foreign exchange rates through 2023. 

Total Revenue is expected to increase by a mid teens percentage  (previously a low double-digit to low teens percentage)  
Core EPS is expected to increase by a mid teens percentage (previously a low double-digit to low teens percentage)

 An increase in Collaboration Revenue is not assumed in the upgraded guidance (previously assumed a substantial increase) ‒ Other operating income is expected to decrease substantially (FY 2023 included a $241m gain on the disposal of Pulmicort Flexhaler US rights, and a $712m one-time gain relating to updates to contractual arrangements for Beyfortus) ‒ The Core Tax rate is expected to be between 18-22%